Patent Application
20230256105
The present invention falls within the field of application of preparations for medical purposes, more specifically, in the field of medicinal preparations containing antigens or antibodies, since it refers to a process for obtaining antigen-presenting vesicles (APV) that enables the coupling of one or more antigens for the preparation of immunogenic compositions, such as vaccines, and immunotherapeutic compounds.
Outer membrane vesicles (OMV) are structures produced by Gram-negative bacteria. These spherical structures are formed from the outer membrane of Gram-negative bacteria and their periplasm. OMVs associate with soluble and insoluble proteins and perform several biological functions.
These vesicles can function as a potent adjuvant in vaccines, given the presence of lipopolysaccharides (LPS) and proteins on their surface, and also as an important carrier.
By knowing this, the present invention proposes a process for obtaining antigen-presenting vesicles (APV) which comprises an immunologically effective amount of at least one OMV, an immunologically effective amount of at least one antigenic protein or peptide, and at least a pair of molecules with complementary affinities (for example, a biotin or a derivative and a protein with affinity to biotin), thus obtaining an antigen-presenting vesicle (APV) that enables the coupling of one or more antigens for the preparation of immunogenic compositions, such as vaccines, and immunotherapeutic compounds.
However, there is a technical problem in the prior art regarding typical conjugation technology, which involves a rigorous treatment of proteins that can result in several difficulties, such as the fact that it increases the risk of denaturation and other modifications of the antigen protein or peptide and the fact that unnecessary modifications/damage to the main structure of the vesicles occur.
In order to solve the existing technical problem, the present invention proposes a process that unexpectedly avoids the risk of denaturation and other modifications of the antigen, thus providing a substantial advantage in preserving the antigenicity of the included proteins.
Likewise, the process of the present invention prevents unnecessary modifications/damage of the main structure of the vesicles because there is no heavy chemical interjection: biotinylation can be controlled to react with specific functional groups in the vesicle. This control can be done by choosing the conjugation reagent as well as the biotin or derivatives to be used. In one embodiment, EDAC, activator molecule, reacts with the carboxylic groups, activating them and making them available for conjugation with the amine groups of the biotin derivative. As the only component directly conjugated to OMVs is biotin, no other parallel conjugation methodologies are needed, as the antigens will always have affinity to biotin.
The state of the art describes processes for obtaining immunotherapeutic compositions that enable the coupling of one or more antigens.
Brazilian patent application no. BR 11 2013 028887 6, published on Aug. 22, 2017, in the name of CHILDREN'S MEDICAL CENTER CORPORATION, entitled: “IMMUNOGENIC COMPOSITION PRESENTING MULTIPLE ANTIGENS, AND METHODS AND USES OF THE SAME” describes an immunogenic composition comprising an immunologically effective amount of at least one antigenic polysaccharide, an immunologically effective amount of at least one peptide or polypeptide antigen, and at least a pair of complementary affinity molecules, their uses and a kit. Differently, the present invention reveals a process for obtaining an antigen-presenting vesicle (APV) that enables the coupling of one or more antigens for the preparation of immunogenic compositions, such as vaccines, and immunotherapeutic compounds through the biotinylation of OMVs and that does not use antigenic polysaccharides as in the document BR 11 2013 028887 6. It is important to emphasize that this document does not disclose the use of OMVs, as proposed by the present invention.
Therefore, no prior art document describes or suggests a process for obtaining of an antigen-presenting vesicle (APV) composed of an outer membrane vesicle of gram-negative bacteria (OMV) that enables the coupling of one or more antigens for the preparation of immunogenic compositions, such as vaccines, and immunotherapeutic compounds.
The present invention will provide significant advantages in the field of medicinal preparations containing antigens or antibodies.
In a first aspect, the present invention refers to a process for obtaining antigen-presenting vesicles (APV) that enables the coupling of one or more antigens, wherein such APV comprises (i) an outer membrane vesicle of gram-negative bacteria (OMV); (ii) at least one antigenic protein or peptide; and (iii) at least a pair of molecules with complementary affinities comprising a first affinity molecule that associates with the vesicle, and a complementary affinity molecule that associates with the protein or peptide.
Thus, the process for obtaining the APV of the present invention is essential to achieve a form of presentation that consists of a vesicle that makes it possible to attach one or more proteins, or a plurality of different protein or peptide antigens.
In that regard, such process comprises the following steps:
a) Conjugating the first affinity molecule (biotin or a derivative) to the vesicle (OMV), optionally with the aid of an activator molecule;
b) Genetically fusioning the complementary affinity molecule (avidin or a derivative such as rizavidin) to protein antigens or peptides; and
c) Coupling the fusion protein obtained in step “b” with the product obtained in step “a”.
The structure and operation of the present invention, together with additional advantages thereof, can be better understood by referring to the attached images and the following description.
Even though the present invention may be susceptible to different embodiments, the drawings and the following detailed discussion show a preferred embodiment with the understanding that the present embodiment is to be considered an exemplification of the principles of the invention and is not intended to limit the present invention to what has been illustrated and described in this report.
The present invention refers to a process for obtaining antigen-presenting vesicles (APV) that enables the coupling of one or more antigens, wherein such APV comprises:
(i) a first affinity molecule that associates with the vesicle (such as a biotin or biotin derivative); and
(ii) a complementary affinity molecule that associates with the protein or peptide (such as avidin or a derivative).
Thus, complementary affinity molecules serve as an indirect link between the vesicle and the antigenic protein or peptide.
The process for obtaining the APV of the present invention is essential to achieve a form of presentation that consists of a vesicle that makes it possible to attach one or more proteins, or a plurality of different protein or peptide antigens.
In that regard, such process comprises the following steps:
a) Conjugating the first affinity molecule (biotin or derivative) to the vesicle (OMV), optionally with the aid of an activator molecule;
b) Obtaining the antigen protein(s) or peptide(s) fusion with the complementary affinity molecule; and
c) Coupling the fusion protein obtained in step “b” with the product obtained in step “a”.
In step “a”, the conjugation reaction of the OMVs with the first affinity molecule is carried out in a suitable solution with the addition of 3% sucrose, in which OMVs are added in the proportion of 1:1 to 1:10 (mass/mass) in relation to the first affinity molecule, and optionally 0.05-0.2 M of activator molecule.
The suitable solution used depends on the type of conjugation used. Suitable solutions include but are not limited to phosphate-buffered saline solution without Ca2+/Mg2+ (PBS) or normal saline (150 mM NaCl in water), all with the addition of 3% sucrose to stabilize OMV membranes. Still, several buffers can be used in the aforementioned appropriate solution, however, these buffers must contain the ideal pH range and have no interfering agent for conjugation, such as EDTA or glycine.
Such mixture it is then kept at a temperature of 4 to 25° C. for 4 to 18 hours. The mixture then proceeds to dialysis against the appropriate solution previously used to eliminate the excess of the first unbound affinity molecule. The most commonly used solutions for such elimination include, but are not limited to, phosphate-buffered saline solution without Ca2+/Mg2+ (PBS), normal saline solution (150 mM NaCl in water) and Tris buffer.
In step “a”, such OMVs come from bacteria selected from the group consisting of N. meningitidis serogroup B or N. lactamica. Preferably, the OMVs come from N. lactamica N.285/03.
Still in step “a”, such first affinity molecule is selected from the group consisting of biotin, a biotin derivative, or a biotin mimic, for example, but not limited to amine-PEG3-biotin ((+)-biotinyl-3-6,9-trioxaundecandiamine) or a derivative or functional fragment thereof, preferably amine-PEG3-biotin ((+)-biotinyl-3-6,9-trioxaundecandiamine), more preferably biotin.
Still in step “a”, such activator molecule is selected from the group consisting of representative coupling agents that include organic compounds, such as thioesters, carbodiimides, succinimide esters, diisocyanatos, glutaraldehydes, diazo benzenes and hexamethylene diamines.
As explained above, it is worth noting that the use of an activator molecule is optional, wherein its use depends on the first affinity molecule used. For example, if a modified biotin is used as first affinity molecule, an activator molecule, such as EDAC (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide) hydrochloride is necessary. However, if another biotin is used, such as an NHS-Biotin, the reaction would take place with OMV's own NH2-groups, not requiring the use of an activator molecule.
In that regard, alternatively, in other embodiments, the first affinity-binding molecule may contain functional groups that bind directly to OMV, without the aid of activating molecules.
In another embodiment, said activator molecule is used to covalently bind the first affinity binding molecule to the vesicle (OMV).
Thus, the first affinity molecule can be attached to the carboxyl, hydroxyl, amino, phenoxy, hemiacetal or mercapto functional groups of the OMV, depending on the conjugation chemistry selected.
In step “b” a fusion protein comprising the antigen protein or peptide fused to the complementary affinity molecule is obtained.
To this end, the complementary affinity molecule is genetically fused to antigen proteins or peptides through the recombinant construction joining the gene of complementary affinity molecule to the gene of the antigen or peptide of interest. Molecular biology techniques such as using conventional polymerase chain reaction (PCR), or gene synthesis can be used to construct a chimeric sequence that encodes a fusion protein.
Such antigen protein or peptide are selected from the group consisting of any antigen that triggers an immune response in an organism, including, but not limited to, immunogenic peptides or proteins, toxins, toxoids, their subunits, or combinations thereof (for example, cholera toxin, tetanus toxoid).
Additionally, the antigen, which is fused to complementary affinity molecule, is selected from the group consisting of any antigen associated with an infectious disease or cancer or immune disease. In some embodiments, the antigen may be a component expressed by any of a variety of infectious agents, including viruses, bacteria, fungi, or parasites.
In some embodiments, the antigen is derived (for example, obtained) from a pathogenic organism. In some embodiments, the antigen is a cancer or tumor antigen, for example an antigen derived from a tumor or cancer cell.
In some embodiments, an antigen derived from a pathogenic organism is an antigen associated with an infectious disease; can be derived from any of a variety of infectious agents, including viruses, bacteria, fungi, or parasites.
A target antigen for use in the process described herein may be expressed by recombinant means and may optionally include an affinity tag or epitope to facilitate purification, which methods are well known in the art. Chemical synthesis of an oligopeptide, free or conjugated to carrier proteins, can be used to obtain the antigen of the invention. Oligopeptides are considered a type of polypeptide.
The antigen can be expressed as a merger with a complementary affinity molecule, for example, but not limited to rizavidin or a functional derivative or fragment thereof. Alternatively, it is also possible to prepare the antigen target and then conjugate it with a complementary affinity molecule, for example, but not limited to rizavidin or a functional derivative or fragment thereof.
An antigen can be obtained by recombinant means or chemical polypeptide synthesis, as well as antigen obtained from natural sources or extracts, it can be purified by means of the physical and chemical characteristics of the antigen from techniques known in the state of the art, such as, for example, by fractionation or chromatography.
In some embodiments, an antigen can be solubilized in water, solutions, or a buffer. Suitable buffers include but are not limited to phosphate-buffered saline solution without Ca2+/Mg2+ (PBS), normal saline solution (NaCl 150 mM in water) and Tris buffer. The antigen not soluble in neutral buffer can be solubilized in 10 mM acetic acid and then diluted to the desired volume with a neutral buffer such as PBS. In the case of the antigen soluble only at acidic pH, acetate-PBS at acidic pH can be used as a diluent after solubilization in dilute acetic acid. Glycerol may be a suitable non-aqueous solvent for use in the process described herein.
Recombinant antigens can be synthesized and purified by protein purification methods using bacterial expression systems, yeast expression systems, baculovirus/insect cell expression system, mammalian cell expression systems, or plant systems or transgenic animals, as they are known by the person skilled in the art.
Fusion proteins can be synthesized and purified by proteinaceous and molecular methods that are well known to those skilled in the art. Molecular biology methods and recombinant heterologous protein expression systems are used. For example, a recombinant fusion protein can be expressed in host cells such as bacteria, mammals, insects, yeasts, or plants, or in transgenic plants or animal hosts.
In one embodiment, in step “b”, an isolated polynucleotide encodes a fusion protein. Conventional polymerase chain reaction (PCR) cloning techniques can be used to construct a chimeric sequence that contains the gene or gene fragment encoding the biotin binding protein, a binding sequence (“linker”) and the gene encoding the antigen, which together encodes a fusion protein, which consists of the joining of two proteins, as described herein. It is important to emphasize that the fusion protein is the genetic construct that joins two proteins that naturally have individual genetic codes that code for specific proteins that will be produced separately, but that when fused, they have a genetic code that codes for the production of these two proteins together and linked.
A coding sequence can be cloned into a general-purpose cloning vector such as, but not limited to pUC19, pBR322, pBLUESCRIPT® (Stratagene, Inc.) or pCR TOPO® (Invitrogen) vectors. Unfused proteins contain only one gene in their construction, that is, a single genetic code, a unique sequence that codes for a single protein.
In some embodiments, in step “b”, wherein the antigen is fused with a complementary affinity molecule, the signal sequence may be located at the N-terminal portion of the complementary affinity molecule.
For example, if an antigen is fused to an avidin-like molecule, the signal sequence can be located in the N-terminal portion of the complementary affinity molecule. In some embodiments, the signal sequence is cleaved from the complementary affinity molecule before the association of the complementary affinity molecule to the first affinity molecule.
Still in step “b”, the complementary affinity molecule is selected from the group consisting of avidin, rizavidin, streptavidin or variants, derivatives, or functional portions thereof.
In some embodiments, the complementary affinity molecule is an avidin-related polypeptide. In specific embodiments, the complementary affinity molecule is rizavidin, such as recombinant rizavidin. In particular, recombinant rizavidin is modified so that it can be expressed in E. coli with high yield. The typical yield is >30 mg per liter of E. coli culture. Rizavidin has a lower sequence homology than egg avidin (22.4% of sequence identity and 35.0% similarity) compared to other avidin-like proteins. The use of modified rizavidin reduces the risk of APV inducing an egg-related allergic reaction in an individual. Furthermore, the antibody against recombinant modified rizavidin does not show apparent cross-reactivity to egg avidin (and vice versa).
In step “c” the coupling of the biotinylated OMVs obtained is performed in step “a” with the fusion proteins obtained in step previous.
To carry out the coupling of biotinylated OMVs with fusion proteins, the conjugated product OMV-first affinity molecule is mixed with the obtained fusion proteins in step “b” in the proportion of 1:1 (mass/mass). This incubation takes place at a temperature ranging from 4 to 25° C. for 4 to 18 hours. After incubation, the mixture is centrifuged at 3000 to 14000 rpm for 3 to 30 minutes to remove insoluble aggregates. The supernatant is then purified.
Ultrafiltration can be used for purification of the APV product obtained in step “c” through membranes of different pore sizes (for example AMICON® or MILLIPORE® membranes). The mixture containing the APVs is ultrafiltered through a membrane with a pore size smaller than the size of the APV. The ultrafiltration retentate will contain the APVs, which can then be subjected to chromatography.
The APV product obtained in step “c” can also be separated from other proteins based on their size, surface charge, hydrophobicity, and affinity for ligands. In some embodiments, a combination of purification steps comprising, for example: (a) ion exchange chromatography, (b) affinity chromatography, (c) hydrophobic interaction chromatography and (d) size exclusion chromatography can be used to purify the obtained APV.
All of these methods are well known in the prior art. It will be evident to a person skilled in the art that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers.
Therefore, surprisingly, the process herein described allows the obtainment of an antigen-presenting vesicle (APV) composed of an outer membrane vesicle of gram-negative bacteria (OMV) that enables the coupling of one or more antigens for the preparation of immunogenic compositions, such as vaccines, and immunotherapeutic compounds.
It should be understood that this invention is not limited to specific methodology, protocols, and reagents, etc. used in the process described herein and as such may vary. The terminology used in this document is intended to describe only particular embodiments and is not intended to limit the scope of the present invention, which is defined only by the claims.
All technical and scientific terms used herein have the same meaning as is commonly understood by a person skilled in the art to which this invention belongs.
The term “antigen-presenting vesicle (APV)” used herein is defined as a platform that allows the delivery of the antigen for efficient activation of the immune system.
The term “immunogenic composition” used herein is defined as a composition capable of eliciting an immune response, such as an antibody or cellular immune response, when administered to an individual. The immunogenic compositions of the present invention may or may not be immunoprotective or therapeutic. When the immunogenic compositions of the present invention prevent, ameliorate, alleviate, or eliminate disease in the subject, then the immunogenic composition may optionally be referred to as a vaccine. As used herein, however, the term immunogenic compositions is not intended to be limited to vaccines.
As used herein, the term “antigen” refers to any substance that elicits an immune response directed against the substance. In some embodiments, an antigen is a peptide or polypeptide, and in other embodiments, it can be any chemical substance or fraction, for example, a carbohydrate, that elicits an immune response directed against the substance.
The term “associated” or “coupled”, as used herein, refers to the linking of two or more molecules by non-covalent bonds. In some embodiments, where the bond of two or more molecules occurs by a non-covalent bond, the two or more molecules can form a complex.
The term “complex”, as used herein, refers to a collection of two or more molecules, spatially connected by means other than a covalent interaction; for example, they can be connected by electrostatic interactions, hydrogen bonds, or by hydrophobic interactions (i.e., van der Waals forces).
The term “conjugation reaction” or “conjugation”, as used herein, refers to a covalent bond formed between a polymer chain and a second molecule. The term “activator molecule” refers to a component that is an intermediate molecule to favor the covalent bonding of a polymer or OMV with another molecule, for example, the first affinity molecule (biotin or a derivative).
As used herein, the term “fused” or “fused” means that at least one protein or peptide is physically associated with a second protein or peptide. In some embodiments, the fusion is typically a covalent bond. Covalent bonding can encompass binding as a fusion protein or chemically coupled bond, for example, via a disulfide bond formed between two cysteine residues.
As used herein, the term “fusion protein” means a protein created by joining two or more polypeptide sequences. Fusion proteins encompassed by this invention include translation products of a chimeric gene construct that joins the DNA sequences encoding one or more antigens, or fragments or mutants thereof, with the DNA sequence encoding a second polypeptide to form a single open reading frame. In other words, a “fusion protein” is a recombinant protein of two or more proteins that are joined by a peptide bond or through several peptides. In a preferred embodiment, the second protein to which the antigens are fused is a complementary affinity molecule which is able of interacting with a first affinity molecule of the complementary affinity pair.
The terms “polypeptide” and “protein” can be used interchangeably to refer to a polymer of amino acid residues linked by peptide bonds and, for the purposes of the claimed invention, have a typical minimum length of at least 25 amino acids. The term “polypeptide” and “protein” may encompass a multimeric protein, for example, a protein containing more than one domain or subunit. The term “peptide”, as used herein, refers to an amino acid sequence linked by peptide bonds containing less than 25 amino acids, for example, between about 4 amino acids and 25 amino acids in length.
Proteins and peptides can be composed of amino acids arranged linearly linked by peptide bonds, whether produced biologically, recombinantly or synthetically, and compounds of naturally occurring or non-naturally occurring amino acids are included in this definition. Full-length proteins and their fragments longer than 25 amino acids are encompassed by the definition of protein. The terms also include polypeptides that have post-translational (for example, signal peptide cleavage) and post-translational polypeptide modifications, such as, for example, disulfide bond formation, glycosylation, acetylation, phosphorylation, lipidation, proteolytic cleavage (for example, cleavage by metalloproteases) and the like. Also, as used herein, a “polypeptide” refers to a protein that includes modifications, such as deletions, additions, and substitutions (generally of a conservative nature, as would be known to a person skilled in the art) in the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, such as through site-directed mutagenesis, or they may be accidental.
The term “functional fragment”, as used in the context of a “functional portion of an antigen”, refers to a portion of the antigen or polypeptide of the antigen that mediates the same effect as the complete portion of the antigen, for example, causes an immune response in an individual or mediates an association with another molecule, for example, comprises at least one epitope.
The term “cytokine”, as used herein, refers to a molecule released from an immune cell in response to stimulation with an antigen. Examples of such cytokines include, but are not limited to: GM-CSF; IL-1α; IL-1p; IL-2; IL-3; IL-4; IL-5; IL-6; IL-7; IL-8; IL-10; IL-12; IL-17A, IL-17F or other family members IL-17, IL-22, IL-23, IFN-α; IFN-α; IFN-γ; MIP-1a; MIP-1β; TGF-β; TNF-α or TNF-ββ. The term “cytokine” does not include antibodies.
As used herein, the term “pathogen” refers to an organism or molecule that causes a disease or disorder in an individual. For example, pathogens include, but are not limited to, viruses, fungi, bacteria, parasites, and other infectious organisms or molecules, as well as taxonomically related macroscopic organisms in the algae, fungi, yeasts, protozoa categories, or the like.
The term “native” refers to the naturally occurring normal polynucleotide sequence that encodes a protein, or a portion thereof, or protein sequence, or portion thereof, respectively, as it normally exists in vivo.
The term “mutant” refers to an organism or cell with any change in its genetic material, in particular a change (i.e., deletion, substitution, addition, or alteration) relating to a wild-type polynucleotide sequence or any relative change to a wild type of protein. The term “variant” can be used interchangeably with “mutant”. Although a change in genetic material is often assumed to result in a change in protein function, the terms “mutant” and “variant” refer to a change in the sequence of a wild-type protein, regardless of whether that change alters the function of the protein (e.g., increases, decreases, confers a new function) or if that change does not affect the function of the protein (e.g. the mutation or variation is silent).
As used herein, the term “heterologous” refers to sequences of nucleic acids, proteins, or polypeptides and means that these molecules are not naturally occurring in that cell. For example, the nucleic acid sequence encoding a fusion antigen protein described herein that is inserted into a cell, e.g., in the context of a protein expression vector, is a heterologous nucleic acid sequence.
The term “recombinant”, when used to describe a nucleic acid molecule, means a polynucleotide of genomic, cDNA, viral, semi-synthetic and/or synthetic origin, which, by virtue of its origin or manipulation, is not associated with all or a portion of the polynucleotide sequences with which it is associated in nature. The term recombinant as used in relation to a recombinant peptide, polypeptide, protein, or fusion protein, means a polypeptide produced by expression of a recombinant polynucleotide. The term recombinant, as used in relation to a host cell, means a host cell into which a recombinant polynucleotide has been introduced. Recombinant is also used herein to refer, with reference to the material (e.g., a cell, a nucleic acid, a protein, or a vector) that the material has been modified by the introduction of a heterologous material.
The term “host cell” refers to any cell that can receive the fusion protein expression vector and express the recombinant protein. The host cell can be bacterial, mammalian, insect, yeast, or plant cells, or in transgenic plants or animal hosts.
The N. lactamica strain used was No. 285/03. Samples kept in cryotubes at −80° C. were thawed at 36° C. and the bacterial suspension was used to inoculate tubes containing Müller-Hinton agar. These tubes were kept inclined at 36° C., in a CO2 atmosphere for 24 h. After this first cell activation culture, the cell mat formed on the agar was resuspended in 3 mL of MC2LAA-YE medium (5.8 g/L of sodium chloride; 0.40 g/L of ammonium chloride; 0.186 g/L of potassium chloride; 0.037 g/L of calcium chloride dihydrate; 0.647 g/L of sodium citrate; 0.616 g/L of magnesium sulfate heptahydrate; 0.001 g/L of hydrated manganese sulfate; 2.36 g/L of L-glutamic acid; 0.21 g/L of L-arginine.HCl; 0.302 g/L of glycine; 0.042 g/L of L-serine; 0.022 g/L of L-cysteine.HCl·H2O; 5 ml/L of glycerol; 15.02 g/L of sodium lactate; 1.062 g/L of dibasic sodium phosphate; 0.171 g/L of monobasic potassium phosphate; 2 g/L of ultrafiltered yeast extract).
These 3 mL were expanded to 100 mL of the same medium, placed in a 300 mL Tunair Flask full baffled, and placed on a 200-250 rpm rotary shaker at 36° C. for 12 h. This culture was used to inoculate 1 L of MC2LAA-YE medium in a 1 L Tunair flask, which was incubated on a 200-250 rpm rotary shaker at 36° C. The inoculum volume was calculated so that the initial OD540 nm of the experiment was approximately 0.15. The OD540 nm was followed during the experiment to identify the end of the stationary phase and then the closure of the culture. The culture was centrifuged at 10,000 rpm, at 10° C., for 45 min and the supernatant was recovered and supplemented with sodium azide at a final concentration of 0.02% to avoid contamination.
The supernatant was filtered on a PES membrane with a pore size of 0.45 μM and ultracentrifuged at 30,000 rpm, 10° C., for 3 h. The precipitate was resuspended in 50 ml PBS+3% sucrose. These 50 mL were then mixed with 50 mL of 100 mM Tris, 2 mM EDTA, 1% SDC (sodium deoxycholate), pH 8.5, and this mixture was kept at room temperature for 15 minutes so that the OMVs could be detoxified and followed by tangential ultrafiltration performed with a 100 kDa cut-off membrane in the LabScale equipment (Labscale TFF System-Merck Millipore). In the same equipment, 6-10 washes with PBS+3% sucrose were performed to eliminate SDC. Finally, the concentration of vesicles was determined by the Bradford colorimetric method.
An aliquot of OMVs was fixed in sodium cacodylate and glutaraldehyde buffer for electron microscopy and evaluation of their integrity.
Step a—Conjugation of Outer Membrane Vesicles (OMVs) with Biotin
Conjugation of OMVs with biotin was performed in PBS buffer, 150 mM NaCl, 3% sucrose, to which 5 mg of OMV, 10 mg of biotin ((+)-biotinyl-3-6,9-trioxaundecandiamine) and 0.1 M of EDAC (N-(3-Dimethylaminopropyl)-N′-Ethyl carbodiimide hydrochloride—Sigma-Aldrich). This mixture was kept at 4° C. for 18 h. The mixture then went on to dialysis against PBS+3% sucrose, to eliminate the excess of unbound biotin. The concentration of OMV-biotin was determined by the Bradford colorimetric method.
Step b—Construction of Recombinant Rizavidin-Antigen Fusion Proteins
To construct a fusion protein between biotin-binding protein (for example, avidin or rizavidin, Rv) and the antigen (for example, any antigenic protein or peptide or the Schistosoma mansoni protein, SmTSP-2), was constructed from a fusion gene containing the rizavidin gene and the antigen gene of interest (SmTSP-2) separated by a DNA sequence encoding a flexible linker region, inserted directly into the 3′ end of the protein gene binding to biotin (rizavidin), to help stabilize the fusion protein. The genes encoding the candidate antigens (full length or fragment) were amplified from the genomic DNA of the pathogens by routine PCR procedures, or synthesized, inserted after the binding region and the fusion gene inserted into the expression vector in E. coli.
For protein expression, plasmids containing target constructs were transformed into E. coli, strain BL21 (DE3), using the standard heat shock procedure. A single colony was picked from the plate (or a glycerol stock was used later) and inoculated into 30 ml of Terrific broth (TB) medium containing Ampicillin (Amp+) for a night culture at 37° C. On day 2, 5 ml of the initial culture was inoculated into 50 ml of TB/Amp+ medium and grown for 3-4 h at 37° C. These 50 mL of the new culture were used as pre-inoculum and, therefore, were inoculated in 1 liter of TB/Amp+ medium, incubated under shaking at 37° C. until reaching OD600=3. After cooling the medium to 23° C., a final concentration of 0.6 mM of IPTG was added to the cultures for an overnight induction.
After cultivation, the bacteria were centrifuged (4000 rpm, 10 min at 4° C.) and resuspended in lysis buffer (150 mM of Tris-HCl pH 7.5; 500 mM of NaCl; 1 mM of PMSF) to perform the mechanical lysis in a high-pressure homogenizer (Panda PLUS 1000 GEA Lab Homogenizer). After lysis, the suspension was centrifuged for 50 min at 12,000 rpm to separate the soluble and insoluble fraction. Soluble proteins went straight to purification. Insoluble proteins were solubilized with 150 mM of Tris-HCl buffer pH 7.5; 500 mM of NaCl; 1 mM of PMSF; 8M of urea. Proteins were purified on a 5 mL HisTrap HP Sepharose column (GE Healthcare), following the manufacturer's instructions, using the Äkta Prime Plus equipment (Amersham Pharmacia).
Recombinant proteins were detoxified to remove lipopolysaccharides (LPS) from E. coli through the Triton X-114 wash method. Each 1 ml of protein was mixed with 10 μl of Triton X-114, shaken vigorously and incubated at 37° C. for 15 min for phase separation. After incubation, the samples were centrifuged at 12,000 rpm for 30 seconds and the upper phase was recovered. This wash was repeated three times to ensure the elimination of the LPS. After this step, the protein was quantified by the Bradford colorimetric method.
Step c—Coupling of OMV-Biotin with the Antigens and Purification
To perform the coupling of biotinylated OMVs with fusion proteins, the OMV-biotin were mixed with rRvAg in the proportion of 1:1 (mass/mass). This incubation took place at 4° C. for 18 h. After incubation, the mixture was centrifuged at 13,200 rpm for 3 min to remove insoluble aggregates. The supernatant was applied to gel filtration chromatography, using the sepharose-200 column, with PBS, Tris buffer or saline solution as the running solution. Peak fractions containing large molecular weight complex were collected and concentrated. The protein content and the proportion of different antigens in the APV-rAg complex were tested by SDS-PAGE with Coomassie blue staining, and the protein/OMV ratio was determined by Western blot using a standard curve with the antigen and specific antibodies.
Tests Performed:
Immunization, Analysis of Antibody and Cytokine Production
C57Bl/6 female mice, obtained from the central vivarium of the Butantan Institute, were kept in the animal testing facility of the Vaccine Development Laboratory according to the rules of the Ethics Committee on the Use of Animals of the Butantan Institute (CEUA/IB) under the CEUA protocol 3314160715.
The vaccines were formulated with sterile saline solution, with the compounds listed below in Table 1. The adjuvant used in this formulation was aluminum hydroxide (Alum), in the proportion (1:10) mass/mass.
The immunization assays followed the scheme of 3 doses applied with an interval of 15 days between them. Serum from these animals was collected before each immunization and also 15 days after the last dose. Thus, it was possible to assess the production of antibodies between each dose. Animals' serums of the same group were analyzed individually by ELISA to verify the total IgG titer and the concentration of IgG1 and IgG2c, specific for the rSmTSP-2 protein.
Splenocytes from immunized mice were isolated and stimulated “in vitro” with the recombinant protein rSmTSP-2 or the respective controls. Supernatants were collected and the production of inflammatory cytokines assessed by Cytometric Bead Array (CBA—BD biosciences inflammatory kit—US), both following the manufacturer's recommendations.
Table 2 presents the Zetasizer characterization of the OMVs and the APV-rSmTSP-2 complex obtained.
Thus, the present invention proposes an easy and highly flexible preparation of an affinity-based antigen-presenting vesicle (APV). The APV obtained is highly specific and stable, being able to remain in the cold for months and retain its potency. Additionally, the amazing process of the present invention is simple enough to ensure high reproducibility, since only a few steps are required, which reduces the risk of batch-to-batch variation, with great industrial advantage.
Thus, the embodiments presented in the present invention do not limit the totality of the possibilities, it will be understood that various omissions, substitutions, and alterations can be made by a person skilled in the art, without departing from the spirit and scope of the present invention.
It is expressly provided that all combinations of elements that perform the same function in substantially the same way to achieve the same results are within the scope of the invention. Substitutions of elements from one described embodiment to another are also fully intended and contemplated.
It is also necessary to understand that the drawings are not necessarily to scale, but that they are only conceptual in nature.
The person skilled in the art will value the knowledge presented herein and may reproduce the invention in the presented embodiments and in other variants, covered in the scope of the claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2020 0132164 | Jun 2020 | BR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/BR2021/050284 | 6/28/2021 | WO |
